MRTX News and Press, Mirati Therapeutics Inc. From 08/05/19

SAN DIEGO , Aug. 5, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter ended June 30, 2019 . Second Quarter Highlights: Initiated the Phase 3 randomized clinical trial, ...

Stericycle (NASDAQ: SRCL ) upgraded to Neutral with a $44 (flat) price target at Baird. More news on: Stericycle, Inc., Abiomed, Inc., Adaptimmune Therapeutics plc, Healthcare stocks news, Stocks on the move, , Read more ...

Biotech Pulse The first half of 2019 had a little bit of everything for biotechs. After a punishing close to last year, with the Nasdaq Biotechnology Index ( IBB ) down 10% for 2018, biotechs rebounded during the first quarter along with the broader market. However, the second quarter provid...

Mirati Therapeutics ( MRTX ) announced that it had formed a collaboration agreement with Novartis ( NVS ) to target patients with advanced solid tumors. This clinical combination is expected to go after a particular subset of the market dealing with solid tumors in a couple of cancer typ...

Outlook Therapeutics (NASDAQ: OTLK ) initiated with Buy rating and $8 (310% upside) at H.C. Wainwright. Shares up  11%  premarket. More news on: Outlook Therapeutics, Inc., Blueprint Medicines Corporation, Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the mov...

SAN DIEGO , July 9, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a clinical collaboration agreement with Novartis to evaluate the combination of MRTX849, Mirati's investigational KRAS G12C inhibitor and TNO...

Editor's note: Seeking Alpha is proud to welcome PylBio Investment as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Welcome to ou...

SAN DIEGO , July 1, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Dr. Julie Cherrington , Ph.D. to its Board of Directors, effective June 27, 2019 . Dr. Cherrington has extensive experience i...

SAN DIEGO , July 1, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Dr. Julie Cherrington , Ph.D. to its Board of Directors, effective June 27, 2019 . Dr. Cherrington has extensive experience i...

SAN DIEGO , June 27, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 2,415,000 shares of its common stock at a public offering price of $97 .00 per share. This includes the exe...